AZ’s Tagrisso extends median overall survival by over 3 years in metastatic, EGFR-mutated lung cancer
pharmafile | September 30, 2019 | News story | Research and Development, Sales and Marketing | AstraZeneca, Cancer, ESMO 2019, Tagrisso, lung cancer, pharma
AstraZeneca took to the stage at the 2019 European Society for Medical Oncology (ESMO) Congress in Barcelona to present new data on Tagrisso (osimertinib) in the first-line treatment of locally-advanced or metastatic epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC).
Tagrisso was shown to present a “statistically significant and clinically meaningful improvement” in overall survival, extending life by a median of 38.6 months compared to 31.8 months with previous standards of care gefitinib and erlotinib.
After three years of treatment, 28% of Tagrisso patients remained on the first-line study treatment versus just 9% in the study’s comparator arm. Additionally, Tagrisso was shown to reduce the risk of central nervous system disease progression by 52% and extend the length of time patients with CNS metastases lived without CNS disease progression or death.
According to AZ, the drug is the only first-line therapy “to deliver a median overall survival of more than three years” in this indication.
“Tagrisso has set a new benchmark in EGFR-mutated non-small cell lung cancer by demonstrating a median overall survival of more than three years,” commented José Baselga, Executive Vice President, Oncology R&D. “We have not before seen survival benefits of this magnitude in any global Phase 3 trial with any such therapy. The ground-breaking data reaffirm the benefit of using Tagrisso first and further support its use as the 1st-line standard of care in this setting.”
Matt Fellows
Related Content
LGC Group opens $100M Organic Chemistry Synthesis Centre of Excellence
LGC Group, a life sciences company, has opened its new Organic Chemistry Synthesis Centre of …
HUTCHMED completes enrolment in phase 3 trial for lung cancer
HUTCHMED has completed patient enrolment for the SANOVO phase 3 clinical trial, investigating the use …
Graphene-based biosensor to support new lung cancer screening test
HydroGraph, a Canadian producer of ultra-pure graphene, has announced a partnership with Hawkeye Bio and …
